Dogwood Therapeutics, Inc (NASDAQ:DWTX) Short Interest Update

Dogwood Therapeutics, Inc (NASDAQ:DWTX) saw a large increase in short interest during the month of December. As of December 31st, there was short interest totaling 81,743 shares, an increase of 61.2% from the December 15th total of 50,720 shares. Based on an average daily volume of 72,259 shares, the short-interest ratio is presently 1.1 days. Currently, 3.7% of the company’s stock are short sold. Currently, 3.7% of the company’s stock are short sold. Based on an average daily volume of 72,259 shares, the short-interest ratio is presently 1.1 days.

Dogwood Therapeutics Price Performance

Shares of NASDAQ:DWTX opened at $2.78 on Friday. Dogwood Therapeutics has a 12 month low of $1.87 and a 12 month high of $29.28. The firm has a market capitalization of $6.37 million, a P/E ratio of -0.11 and a beta of 1.90. The company’s fifty day moving average price is $5.17 and its 200 day moving average price is $5.25.

Dogwood Therapeutics (NASDAQ:DWTX) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($8.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($6.97). On average, sell-side analysts anticipate that Dogwood Therapeutics will post -6.43 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on DWTX. HC Wainwright lifted their price objective on shares of Dogwood Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Tuesday, September 30th. Wall Street Zen cut Dogwood Therapeutics to a “strong sell” rating in a research note on Saturday, December 13th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dogwood Therapeutics in a research report on Monday, December 22nd. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Dogwood Therapeutics currently has an average rating of “Hold” and an average price target of $12.00.

About Dogwood Therapeutics

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.